label int64 1 1 | id stringlengths 10 12 | original_id stringlengths 8 9 | text stringlengths 347 29.5k |
|---|---|---|---|
1 | 171723953_0 | 171723953 | PACIFIC DRILLING S.A.
Form 20-F
Filed on 24-Feb-2017 Period 31-Dec-2016 Accession number: 0001558370-17-001010
Included Items
1. 20-F 2. EX-1.1 3. EX-4.16 4. EX-4.9 5. EX-8.1 6. EX-12.1 7. EX-12.2 8. EX-13.1 9. EX-13.2 10. EX-15.1 11. XBRL (render)
UNITED STATES SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 2... |
1 | 171723953_1 | 171723953 | COMPANY REPORT PURSUANT TO SECTION 13 OR 15 (d) OF THE SECURITIES EXCHANGE ACT OF 1934
Commission file number 001-35345
PACIFIC DRILLING S.A.
(Exact name of Registrant as specified in its charter)
Not Applicable (Translation of Registrant's name into English)
Luxembourg (Jurisdiction of incorporation or organization... |
1 | 171723953_2 | 171723953 |
Securities for which there is a reporting obligation pursuant to Section 15(d) of the Act. None. Indicate the number of outstanding shares of each of the issuer's classes of capital or common stock as of the close of the period covered by the annual report.
As of December 31, 2016, there were 21,183,852 shares outstan... |
1 | 171723953_3 | 171723953 | Data File required to be submitted and posted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit and post such files). Yes No
Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, or... |
1 | 171723953_b0 | 171723953 | 2015
Variable Interest Entity [Line Items]
Assets
$ 10,020 $ 17,612
Liabilities
(2,247)
(19,250)
Net carrying amount
$ 7,773
$ (1,638)
Variable Interest Entities Customs Bonds (Details)
$ in Millions
Dec. 31, 2016 USD ($)
Surety Bond | Primary Beneficiary
Loss Contingencies [Line Items]
Contingent liabi... |
1 | 171723953_b1 | 171723953 |
Concentration risk percentage
1.00%
20.00%
Segments and Geographic Areas - Percentage of Revenue Earned by
Geographical Area (Detail) segment
12 Months Ended Dec. 31, 2016 Dec. 31, 2015 Dec. 31, 2014
Concentration Risk [Line Items]
Number of reportable segment
1
Geographic Concentration Risk | Sales | Gulf of... |
1 | 171725336_0 | 171725336 | Prothena Corp Plc
Form 10-K
Filed on 27-Feb-2017 Period 31-Dec-2016 Accession number: 0001559053-17-000005
Included Items
1. 10-K: FORM 10-K 2. EX-10.6: EXHIBIT 10.6 COMMERCIAL SUPPLY
AGREEMENT WITH RENTSCHLER 3. EX-10.27: EXHIBIT 10.27 DAVID MCNINCH
SEPARATION AGREEMENT 4. EX-10.28: EXHIBIT 10.28 OFFER LETTER -
CARO... |
1 | 171725336_1 | 171725336 | SECTION 302 9. EX-32.1: EXHIBIT 32.1 SECTION 906 CERTIFICATION 10. XBRL (render)
UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
______________________________________
FORM 10-K
______________________________________
(Mark One)
x ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES... |
1 | 171725336_2 | 171725336 | )
Registrant's telephone number, including area code: 011-353-1-236-2500
Securities registered pursuant to Section 12(b) of the Act:
Title of Each Class Ordinary Shares, par value $0.01 per share
Name of Each Exchange on Which Registered The Nasdaq Global Select Market
Securities registered pursuant to Section 12(g... |
1 | 171725336_3 | 171725336 | on its corporate Web site, if any, every Interactive Data File required to be submitted and posted pursuant to Rule 405 of Regulation S-T (§232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit and post such files). Yes x No o
Indicate by check ... |
1 | 171725336_b0 | 171725336 | , 2017
Dec. 31, 2016
[1]
$ (316)
$ 2,300
8,400 [1] $ (316)
[1] As a result of the January 2017 Assignment of the Former SSF Facility, the Company's operating lease commitments will be lowered by $8.4 million over the periods reflected in the table above. In addition, the Company will not receive the future minimu... |
1 | 171725336_b1 | 171725336 | ownership interest acquired
Issuance of ordinary shares to Elan, shares
Perrigo [Member] | Ordinary Shares
Related Party Transaction [Line Items]
Shares sold pursuant to underwritten public offering
3,182,253
Share price
$ 26
Chief Regulatory Officer [Member]
Related Party Transaction [Line Items]
Amount pai... |
1 | 171725450_0 | 171725450 | Horizon Pharma Plc
Form 10-K
Filed on 27-Feb-2017 Period 31-Dec-2016 Accession number: 0001564590-17-002491
Included Items
1. 10-K 2. EX-10.64 3. EX-10.72 4. EX-10.73 5. EX-10.74 6. EX-21.1 7. EX-23.1 8. EX-31.1 9. EX-31.2 10. EX-32.1 11. EX-32.2 12. XBRL (render)
UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Wa... |
1 | 171725450_1 | 171725450 | HORIZON PHARMA PUBLIC LIMITED COMPANY
(Exact name of Registrant as specified in its charter)
Ireland
(State or other jurisdiction of incorporation or organization)
Not Applicable
(I.R.S. Employer Identification No.)
Connaught House, 1st Floor 1 Burlington Road, Dublin 4, D04 C5Y6, Ireland
(Address of principal execu... |
1 | 171725450_2 | 171725450 | No.
Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requ... |
1 | 171725450_3 | 171725450 | er, or a smaller reporting company.
Large accelerated filer
Accelerated filer
Non-accelerated filer
(Do not check if a smaller reporting company)
Smaller reporting company
Indicate by check mark whether the registrant is a shell company (as defined by Rule 12b-2 of the Exchange Act). Yes No
The aggregat... |
1 | 171725450_b0 | 171725450 | $ 0.09 $ (0.28) $ 0.15 $ 0.02 $ 0.20 $ (0.16) $ (1.04) $ 0.25 $ (3.15)
Schedule II - Valuation and Qualifying Accounts (Detail) -
USD ($) $ in Thousands
12 Months Ended Dec. 31, 2016 Dec. 31, 2015 Dec. 31, 2014
Valuation And Qualifying Accounts Disclosure [Line Items]
Valuation Allowances and Reserves, Reserves o... |
1 | 171725450_b1 | 171725450 | 21 113,141 981,120 757,044 296,955
160,598 123,541 176,252 127,457 176,965 165,294 110,995 84,288 587,848 537,542 218,202
(130,108) (21,322) 31,467 (27,204) 38,049 45,732 (33,173) 4,764
$ (147,167)
$
55,372
$
(8,491)
$ (130,542)
$
(5,870)
$
14,984
$ (45,406)
$ 23,994 $ 3,277
$
31,814
$ (19,553)
$ (0.8... |
1 | 171729765_0 | 171729765 | Intelsat S.A.
Form 20-F
Filed on 28-Feb-2017 Period 31-Dec-2016 Accession number: 0001193125-17-060212
Included Items
1. 20-F: FORM 20-F 2. EX-2.11: EXHIBIT 2.11 3. EX-2.19: EXHIBIT 2.19 4. EX-2.25: EXHIBIT 2.25 5. EX-2.27: EXHIBIT 2.27 6. EX-2.29: EXHIBIT 2.29 7. EX-4.52: EXHIBIT 4.52 8. EX-4.53: EXHIBIT 4.53 9. EX-... |
1 | 171729765_1 | 171729765 | 1: EXHIBIT 8.1 18. EX-12.1: EXHIBIT 12.1 19. EX-12.2: EXHIBIT 12.2 20. EX-13.1: EXHIBIT 13.1 21. EX-13.2: EXHIBIT 13.2 22. EX-15.1: EXHIBIT 15.1 23. XBRL (render)
Table of Contents
UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 20-F
(Mark One)
REGISTRATION STATEMENT PURSUANT TO SECTI... |
1 | 171729765_2 | 171729765 | ANGE ACT OF 1934
Commission file number: 001-35878
INTELSAT S.A.
(Exact name of Registrant as specified in its charter)
N/A
(Translation of Registrant's name into English)
Grand Duchy of Luxembourg
(Jurisdiction of incorporation or organization)
4 rue Albert Borschette Luxembourg
Grand-Duchy of Luxembourg L-1246
(Add... |
1 | 171729765_3 | 171729765 | Name of Each Exchange On Which Registered
New York Stock Exchange New York Stock Exchange
Securities registered or to be registered pursuant to Section 12(g) of the Act: None
Securities for which there is a reporting obligation pursuant to Section 15(d) of the Act: None
Indicate the number of outstanding shares of e... |
1 | 171729765_b0 | 171729765 | (1,389,126) (1,063) (104,656) 167,800 63,144
64,363
(5,821)
(5,821)
(24,418) 360 3,984 (33,943) (1,069) 12,209 (8,744) (51,621) (5,473) 1,448 50,769 52,217
(1,887,338)
639,603 (16,960) 4,178 (355,586)
(174) 271,061
13,087
Debt issuance costs Other payments for satellites
Capital contribution from parent Dividends to... |
1 | 171729765_b1 | 171729765 |
(287,660)
Purchase of cost method investment
4,000
Other investing activities
Net cash provided by (used in) investing activities
399,168
Cash flows from financing activities:
Disbursements for intercompany loans
376,570
28,423 (25,000) 432 (754,798)
86,316 (916,697) (18,405) 1,600 (847,186) (931) 26,497 63,1... |
1 | 171732242_0 | 171732242 | Medidata Solutions, Inc.
Form 10-K
Filed on 28-Feb-2017 Period 31-Dec-2016 Accession number: 0001453814-17-000063
Included Items
1. 10-K: FORM 10-K 2. EX-21.1: SUBSIDIARIES OF MEDIDATA
SOLUTIONS, INC. 3. EX-23.1: CONSENT OF DELOITTE & TOUCHE
LLP 4. EX-31.1: CERTIFICATION OF CEO PURSUANT
TO RULE 13A-14(A) OR 15D-14(A)... |
1 | 171732242_1 | 171732242 | BRL (render)
Table of Contents
UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
_____________________________________
FORM 10-K
_____________________________________
ý ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934
For the fiscal year ended December 31, 2... |
1 | 171732242_2 | 171732242 | (b) of the Exchange Act:
Title of each class
Name of each exchange on which registered
Common Stock, par value $0.01 per share
The NASDAQ Stock Market LLC
Securities registered under Section 12(g) of the Exchange Act: None
Indicate bycheck mark if the registrant is a well-known seasoned issuer, as defined in Rule... |
1 | 171732242_3 | 171732242 | of Regulation S-T (§ 232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit and post such files). ý Yes ¨ No
Indicate bycheck mark if disclosure of delinquent filers pursuant to Item 405 of Regulation S-K is not contained herein, and will not be ... |
1 | 171732242_b0 | 171732242 | )
Net income
$ 4,937
$ 5,848
Basic earnings per share
$ 0.09
$ 0.11
Diluted earnings per share
$ 0.09
$ 0.10
Diluted weighted average common shares outstanding
56,604
56,365
Adjustment [Member]
Provision for income taxes
$ (1,273)
$ 1,273
Net income
$ 1,273
$ (1,273)
Basic earnings per share
$ 0.02... |
1 | 171732242_b1 | 171732242 | $ 0.19 $ 0.13 $ 0.11
$ 0.08
$ 0.13 $ 0.09 $ 0.03 $ 0.00 $ 0.52 $ 0.25 $ 0.12
Diluted earnings per share $ 0.19 $ 0.13 $ 0.11
$ 0.08
$ 0.12 $ 0.08 $ 0.03 $ 0.00 $ 0.51 $ 0.23 $ 0.11
Diluted weighted average common shares outstanding
57,249 56,540 55,247
Actual [Member]
Provision for income taxes
$ 1,688
$ (1,... |
1 | 171735289_0 | 171735289 | Oxford Immunotec Global PLC
Form 10-K
Filed on 01-Mar-2017 Period 31-Dec-2016 Accession number: 0001437749-17-003451
Included Items
1. 10-K: FORM 10-K 2. EX-10.20: EXHIBIT 10.20 3. EX-21.1: EXHIBIT 21.1 4. EX-23.1: EXHIBIT 23.1 5. EX-31.1: EXHIBIT 31.1 6. EX-31.2: EXHIBIT 31.2 7. EX-32: EXHIBIT 32 8. XBRL (render)
... |
1 | 171735289_1 | 171735289 | CHANGEACT OF 1934
For the transition period from to
Commission File Number 001-36200
OXFORD IMMUNOTEC GLOBAL PLC
(Exact name of registrant as specified in its charter)
England and Wales
(State or Other Jurisdiction of Incorporation or Organization)
98-1133710
(I.R.S. Employer Identification No.)
94C Innovation Dr... |
1 | 171735289_2 | 171735289 | by check mark if the registrant is not required to file reports pursuant to Section 13 or 15(d) of the Act. Yes No
Indicate by check mark whether the registrant: (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such s... |
1 | 171735289_3 | 171735289 | -K.
Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer or a smaller reporting company. See the definitions of "large accelerated filer," "accelerated filer" and "smaller reporting company" in Rule 12b-2 of the Exchange Act (check one):
Large acce... |
1 | 171735289_b0 | 171735289 | (34,000) (145,000) 2,916,000 359,000
2,627,000
(97,000) $ (14,000)
Note 17 - Acquisition Activity - Business Acquisition,
Consideration Transferred (Details) - USD ($) $ in Thousands
Oct. 12, 2016 Jul. 31, 2014
Immunetics [Member]
Cash consideration
$ 6,000
Estimated fair value of contingent consideration 3,444... |
1 | 171735289_b1 | 171735289 | ]
Intangible assets
860,000
Immunetics [Member] | Customer Relationships [Member]
Intangible assets
400,000
Immunetics [Member] | Trade Names [Member]
Intangible assets
290,000
Immunetics [Member] | Grants [Member]
Intangible assets
50,000
Immunetics [Member] | In Process Research and Development, Indefinit... |
1 | 171737090_0 | 171737090 | Endo International Plc
Form 10-K
Filed on 01-Mar-2017 Period 31-Dec-2016 Accession number: 0001593034-17-000009
Included Items
1. 10-K 2. EX-10.14: FORM OF STOCK OPTION
AGREEMENT 3. EX-10.15: FORM OF STOCK AWARD
AGREEMENT 4. EX-10.16: FORM OF PERFORMANCE AWARD
AGREEMENT 5. EX-10.17: FORM OF LTCI AWARD
AGREEMENT 6. EX... |
1 | 171737090_1 | 171737090 | 14. XBRL (render)
Table of Contents
UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, DC 20549
____________________________________________________________________________________________
FORM 10-K
____________________________________________________________________________________________
(Mark One)
... |
1 | 171737090_2 | 171737090 | Number, Including Area Code)
Securities registered pursuant to Section 12(b) of the Act:
Not Applicable (Zip Code)
Title of each class Ordinary shares, nominal value $0.0001 per share
Name of each exchange on which registered The NASDAQ Global Market, The Toronto Stock Exchange
Securities registered pursuant to Se... |
1 | 171737090_3 | 171737090 | and posted on its corporate website, if any, every interactive data file required to be submitted and Yes x No o posted pursuant to Rule 405 of Regulation S-T duringthe preceding12 months.
Indicate by check mark if disclosure of delinquent filers pursuant to Item 405 of Regulation S-K is not contained herein, and wil... |
1 | 171737090_b0 | 171737090 | ENTS, END OF PERIOD
$ 1,576,000 $ 1,535,000 $ 568,000
SCHEDULE I -- Condensed Financial Information of the
Registrant - Narrative (Details) - USD ($)
12 Months Ended Feb. 28, 2014 Dec. 31, 2016 Dec. 31, 2015 Dec. 31, 2014
Condensed Financial Statements, Captions [Line Items]
Proceeds from dividends
$ 54,800,000 ... |
1 | 171737090_b1 | 171737090 | ) investing activities
54,770,000 (1,986,752,000) 0
FINANCING ACTIVITIES:
Payments of tax withholding for restricted shares
(11,500,000) (15,398,000) (3,607,000)
Exercise of options
1,952,000 27,217,000 29,766,000
Repurchase of ordinary shares
0
(250,088,000) 0
Issuance of ordinary shares
0
2,300,000,000 0
... |
1 | 171738541_0 | 171738541 | Criteo S.A.
Form 10-K
Filed on 01-Mar-2017 Period 31-Dec-2016 Accession number: 0001576427-17-000021
Included Items
1. 10-K 2. EX-4.3: EXHIBIT 4.3 3. EX-10.9: EXHIBIT 10.9 4. EX-21.1: EXHIBIT 21.1 5. EX-23.1: EXHIBIT 23.1 6. EX-31.1: EXHIBIT 31.1 7. EX-31.2: EXHIBIT 31.2 8. EX-32.1: EXHIBIT 32.1 9. XBRL (render)
UN... |
1 | 171738541_1 | 171738541 | 15(D) OF THESECURITIES EXCHANGEACT OF 1934
for the transition period from
to
Commission file number: 001-36153
Criteo S.A. (Exact name of registrant as specified in its charter)
France (State or other jurisdiction of incorporation or
organization)
Not Applicable (I.R.S. Employer Identification Number)
32, rue B... |
1 | 171738541_2 | 171738541 | registrant is a well-known seasoned issuer, as defined in Rule 405 of the Securities Act. Yes x No ¨
Indicate by check mark if the registrant is not required to file reports pursuant to Section 13 or Section 15(d) of the Act. Yes ¨ No x
Indicate by check mark whether the registrant (1) has filed all reports required t... |
1 | 171738541_3 | 171738541 | or information statements incorporated by reference in Part III of this Form 10-K or any amendment to this Form 10-K. ¨
Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer or a smaller reporting company. See the definitions of "large accelerated fil... |
1 | 171738541_b0 | 171738541 | , 2015 Dec. 31, 2014
Revenues from External Customers and Long-Lived Assets [Line Items]
Revenue
$ 1,799,146 $ 1,323,169 $ 988,249
United States
Revenues from External Customers and Long-Lived Assets [Line Items]
Revenue
630,047 419,742 237,385
Germany
Revenues from External Customers and Long-Lived Assets [Li... |
1 | 171738541_b1 | 171738541 |
EMEA
Revenues from External Customers and Long-Lived Assets [Line Items]
Revenue
660,523 541,105 485,986
Asia-Pacific
Revenues from External Customers and Long-Lived Assets [Line Items]
Revenue
$ 407,750 $ 276,411 $ 198,827
Breakdown of Revenue and Non-Current Assets by Geographical Areas -
Narrative (Detail... |
1 | 171740122_0 | 171740122 | SYNTEL INC
Form 10-K
Filed on 02-Mar-2017 Period 31-Dec-2016 Accession number: 0001193125-17-066104
Included Items
1. 10-K 2. EX-10.5 3. EX-10.19 4. EX-10.20 5. EX-10.21 6. EX-10.22 7. EX-21 8. EX-23 9. EX-31.1 10. EX-31.2 11. EX-31.3 12. EX-32 13. XBRL (render)
Table of Contents
UNITED STATES SECURITIES AND EXCHA... |
1 | 171740122_1 | 171740122 | .R.S. Employer Identification No.)
525 E. Big Beaver Road, Suite 300, Troy, Michigan
(Address of principal executive offices)
Registrant's telephone number, including area code: (248) 619-2800
Securities registered pursuant to Section 12(b) of the Act:
48083
(Zip Code)
Title of Class
Common Stock, no par value
Name... |
1 | 171740122_2 | 171740122 | filing requirements for the past 90 days. Yes No
Indicate by check mark whether the Registrant has submitted electronically and posted on its corporate Website, if any, every Interactive Data File required to be submitted and
posted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such ... |
1 | 171740122_3 | 171740122 |
Smaller Reporting Company
Indicate by check mark whether the Registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act). Yes No
The aggregate market value of the Common Stock held by non-affiliates of the Registrant as of the last business day of the Registrant's most recently completed second ... |
1 | 171740122_b0 | 171740122 | with Various Banks Outstanding (Detail) -
USD ($) $ in Millions
Dec. 31, 2016 Dec. 31, 2015
Schedule of Fair Value of Separate Accounts by Major Category of Investment [Line Items]
Term deposits outstanding
$ 6.8
$ 413.7
Short term investments
Schedule of Fair Value of Separate Accounts by Major Category of Inv... |
1 | 171740122_b1 | 171740122 | asured at Fair Value on Recurring Basis (Detail) - USD ($) $ in Millions
Dec. 31, 2016 Dec. 31, 2015
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Available for sale securities
$ 15.0
$ 126.5
Term deposits
6.8
413.7
Interest rate swaps
0.5
Total assets measured ... |
1 | 171744491_0 | 171744491 | NXP Semiconductors N.V.
Form 20-F
Filed on 03-Mar-2017 Period 31-Dec-2016 Accession number: 0001193125-17-068664
Included Items
1. 20-F 2. EX-4.21 3. EX-4.22 4. EX-10.22 5. EX-10.33 6. EX-12.1 7. EX-12.2 8. EX-13.1 9. EX-13.2 10. EX-21.1 11. EX-23 12. XBRL (render)
Table of Contents
As filed with the Securities an... |
1 | 171744491_1 | 171744491 | TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934
OR
SHELL COMPANY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934
Date of event requiring this shell company report
For the transition period from
to
Commission file number 001-34841
NXP Semiconductors N.V.
(Exact name of ... |
1 | 171744491_2 | 171744491 | UR) 0.20 per share
Name of each exchange on which registered
The NASDAQ Global Select Market
Securities registered or to be registered pursuant to Section 12(g) of the Act.
None
(Title of class)
Securities for which there is a reporting obligation pursuant to Section 15(d) of the Act.
Common shares--par value EUR ... |
1 | 171744491_3 | 171744491 | required to file reports pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 from their obligations under those Sections.
Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 1... |
1 | 171744491_b0 | 171744491 | 882 251
[1] 285 183
[1] 906 922
[1] 984 166
[1] 623 52
[1] 550 1
[1] 369
[1] 231 378
[1] 1,668 $ 399
$ 6,101 2,922
3,135 360
177 161
415 1,115
526 186
392 98
316 2
268 1
41 473
831 $ 526
$ 5,647 1,123
2,756 116
171 169
396 5
452 200
450 80
245 1
287 1
47 79
843 $ 472
[1] Revenue attributed to geographic areas is bas... |
1 | 171744491_b1 | 171744491 | segment under ASC 280 "Segment Reporting".
Segments and Geographical Information - Geographical Segment Report (Detail) -
USD ($) $ in Millions Segment Reporting Information [Line Items] Revenue Property, plant and equipment China [Member] Segment Reporting Information [Line Items] Revenue Property, plant and equipm... |
1 | 171751530_0 | 171751530 | Talend SA
Form 20-F
Filed on 07-Mar-2017 Period 31-Dec-2016 Accession number: 0001558370-17-001378
Included Items
1. 20-F 2. EX-1.1 3. EX-8.1 4. EX-12.1 5. EX-12.2 6. EX-12.3 7. EX-15.1
Table of Contents
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549
FORM 20-F
(Mark One)
REGISTRATION STA... |
1 | 171751530_1 | 171751530 | ANYREPORT PURSUANT TO SECTION 13 OR15(d) OF THESECURITIES EXCHANGEACT OF 1934
Commission file number 001-37825
Talend S.A.
(Exact name of Registrant as specified in its charter)
Not Applicable (Translation of Registrant's name into English)
France (Jurisdiction of incorporation or organization) 9, rue Pages, 92150 Su... |
1 | 171751530_2 | 171751530 | share*
* Not for trading, but only in connection with the listing of the American Depositary Shares on The NASDAQ Stock Market LLC.
Securities registered or to be registered pursuant to Section 12(g) of the Act:
None
Securities for which there is a reporting obligation pursuant to Section 15(d) of the Act: None
I... |
1 | 171751530_3 | 171751530 | preceding 12 months (or
for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days. Yes No
Indicate by check mark whether the registrant has submitted electronically and posted on its corporate Web site, if any, every Int... |
1 | 171751530_b0 | 171751530 | that, to the best of his knowledge:
1. The Company's Annual Report on Form 20-F for the fiscal year ended December 31, 2016, to which this Certification is attached as Exhibit 13.3 (the "Annual Report"), fully complies with the requirements of Section 13(a) or Section 15(d) of the Exchange Act, and
2. The information... |
1 | 171751530_b1 | 171751530 | the Company's ability to record, process, summarize and report financial information and
b. Any fraud, whether or not material, that involves management or other employees who have a significant role in the Company's internal control over financial reporting.
Date: March 6, 2017
TALEND S.A.
By:
/s/ THOMAS TUCHSCHE... |
1 | 171754001_0 | 171754001 | ASTRAZENECA PLC
Form 20-F
Filed on 07-Mar-2017 Period 31-Dec-2016 Accession number: 0000950103-17-002275
Included Items
1. 20-F: FORM 20-F 2. EX-4.3: EXHIBIT 4.3 3. EX-4.5: EXHIBIT 4.5 4. EX-7.1: EXHIBIT 7.1 5. EX-8.1: EXHIBIT 8.1 6. EX-12.1: EXHIBIT 12.1 7. EX-12.2: EXHIBIT 12.2 8. EX-13.1: EXHIBIT 13.1 9. EX-15.1: ... |
1 | 171754001_1 | 171754001 | ITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 20-F
(Mark One) o REGISTRATION STATEMENT PURSUANT TO SECTION 12(b) OR (g) OF THESECURITIES EXCHANGEACT OF 1934
OR
x ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THESECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2016
O... |
1 | 171754001_2 | 171754001 | CB2 0AA England
(Address of principal executive offices)
Adrian Kemp AstraZeneca PLC 1 Francis Crick Avenue Cambridge Biomedical Campus Cambridge CB2 0AA
England Telephone: +44 20 3749 5000 Facsimile number: +44 1223 352 858 (Name, Telephone, E-Mail or Facsimile number and Address of Company Contact Person)
Securiti... |
1 | 171754001_3 | 171754001 |
3.375% Notes due 2025
The New York Stock Exchange
6.450% Notes due 2037
The New York Stock Exchange
4.000% Notes due 2042
The New York Stock Exchange
4.375% Notes due 2045
The New York Stock Exchange
* Not for trading, but only in connection with the registration of American Depositary Shares representing suc... |
1 | 171754001_b0 | 171754001 | /A
N/A
N/A
N/A
N/A
N/A
N/A
N/A
N/A
1 Regular review of the data is carried out to ensure accuracy and consistency. This has led to slight changes in the data for previous years. None of the changes is statistically significant. The data quoted in this Annual Report are generated from the revised data. 2 Includ... |
1 | 171754001_b1 | 171754001 | travel, goods transport, waste incineration, and first tier active pharmaceutical ingredients and formulation & packaging suppliers (>90% of category spend, energy only) Downstream emissions from HFA propellants released during patient use of our inhaled medicines 2016-2025 Strategy `Operational Footprint' KPI: Scope ... |
1 | 171755878_0 | 171755878 | Sucampo Pharmaceuticals, Inc.
Form 10-K
Filed on 08-Mar-2017 Period 31-Dec-2016 Accession number: 0001171843-17-001354
Included Items
1. 10-K: FORM 10-K 2. EX-10.44: EXHIBIT 10.44 3. EX-10.45: EXHIBIT 10.45 4. EX-12.1: EXHIBIT 12.1 5. EX-21: EXHIBIT 21 6. EX-23.1: EXHIBIT 23.1 7. EX-23.2: EXHIBIT 23.2 8. EX-31.1: EXH... |
1 | 171755878_1 | 171755878 | REPORTPURSUANTTO SECTION 13 OR 15(d) OF THESECURITIES EXCHANGEACTOF 1934
For the fiscal year ended December 31, 2016
o TRANSITION REPORTPURSUANTTO SECTION 13 OR 15(d) OF THESECURITIES EXCHANGEACTOF 1934
For the transition period from __________ to __________.
Commission File Number: 001-33609
SUCAMPO PHARMACEUTIC... |
1 | 171755878_2 | 171755878 | Global Market
Securities registered pursuant to Section 12(g) of the Exchange Act: None
Indicate by check mark if the registrant is a well-known seasoned issuer, as defined in Rule 405 of the Securities Act. Yes No þ
Indicate by check mark if the registrant is not required to file reports pursuant to Section 13 or... |
1 | 171755878_3 | 171755878 | check mark if disclosure of delinquent filers pursuant to Item 405 of Regulation S-K (§ 229.405 of this chapter) is not contained herein, and will not be contained, to the best of registrant's knowledge, in definitive proxy or information statements incorporated by reference in Part III of this Form 10-K or any amendm... |
1 | 171755878_b0 | 171755878 | 000
Valuation Allowances and Reserves, Additions for Charges to Cost and Expense $ 1,200,000
Schedule II - Valuation and Qualifying Accounts (Details)
- USD ($) Charged to Costs and Expenses Deductions Allowance for Doubtful Accounts [Member] Balance Charged to Costs and Expenses Deductions Balance Valuation Allowan... |
1 | 171755878_b1 | 171755878 | 580 9,654 53,876 44,459 27,231
Net income (loss)
$ 15,283 $ 8,092 $ (832) $ (4,057) $ 10,151 $ 7,236 $ 9,576 $ 6,408 $ 18,487 $ 33,371 $ 13,128
Basic (in dollars per share) $ 0.36 $ 0.19 $ (0.02) $ (0.10) $ 0.24 $ 0.16 $ 0.21 $ 0.14 $ 0.43 $ 0.76 $ 0.30
Diluted (in dollars per share) $ 0.34 $ 0.19 $ (0.02) $ (0.10)... |
1 | 171763960_0 | 171763960 | Adaptimmune Therapeutics PLC
Form 10-K
Filed on 13-Mar-2017 Period 31-Dec-2016 Accession number: 0001104659-17-016024
Included Items
1. 10-K 2. EX-10.16 3. EX-10.17 4. EX-10.18 5. EX-10.19 6. EX-10.20 7. EX-10.21 8. EX-23.1 9. EX-31.1 10. EX-31.2 11. EX-32.1 12. EX-32.2 13. XBRL (render)
Table of Contents
UNITED S... |
1 | 171763960_1 | 171763960 | UNE THERAPEUTICS PLC
(Exact name of Registrant as specified in its charter)
England and Wales (State or other jurisdiction of incorporation or organization)
Not Applicable (I.R.S. Employer Identification No.)
101 Park Drive, Milton Park Abingdon, Oxfordshire OX14 4RY
United Kingdom (Address of principal executive of... |
1 | 171763960_2 | 171763960 | the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days.
x Yes... |
1 | 171763960_3 | 171763960 | accelerated filer, a non-accelerated filer, or a smaller reporting company. See the definitions of "large accelerated filer," "accelerated filer" and "smaller reporting company" in Rule 12b-2 of the Exchange Act.
Large accelerated filer o Non-accelerated filer o (Do not check if a smaller reporting company)
Accelera... |
1 | 171763960_b0 | 171763960 |
Income taxes
Tax rate (as a percent)
17.00% 19.00%
Internal Revenue Service (IRS)
Income taxes
Tax rate (as a percent)
34.00% 34.00% 34.00%
34.00% 34.00%
Tax rate, deferred taxes (as a percent)
34.00% 34.00% 40.00%
Income taxes - Net Operating Loss and Expenditure Credit
Carryforwards (Details) $ in Million... |
1 | 171763960_b1 | 171763960 | %
Income taxes - Change in Tax Rate (Details)
$ in Thousands, £ in Millions
Apr. 01, 2020
Apr. 01, 2017
6 Months Ended
Dec. 31, 2015
Dec. 31, 2016
GBP (£)
12 Months Ended
Dec. 31, 2016
USD ($)
Dec. 31, 2015
Jun. 30, 2015
Jun. 30, 2014
Income taxes
Effect of changes in tax rates on Consolidated statement of... |
1 | 171767507_0 | 171767507 | LUXFER HOLDINGS PLC
Form 20-F
Filed on 14-Mar-2017 Period 31-Dec-2016 Accession number: 0001047469-17-001569
Included Items
1. 20-F 2. EX-2.3 3. EX-2.4 4. EX-2.5 5. EX-2.6 6. EX-2.7 7. EX-12.1 8. EX-12.2 9. EX-13.1 10. EX-13.2 11. EX-15.1 12. EX-15.2
Use these links to rapidly review the document TABLE OF CONTENTS ... |
1 | 171767507_1 | 171767507 | ITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2016
OR
o TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934
OR
o SHELL COMPANY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934
Commission File Number 001-35370
LUXFER HOLDINGS PLC... |
1 | 171767507_2 | 171767507 | Title of each class
Name of each exchange on which registered
Ordinary Shares, nominal value £0.50 each
New York Stock Exchange*
American Depositary Shares, each representing an Ordinary Share of nominal value £0.50 each
New York Stock Exchange
Securities registered or to be registered pursuant to Section 12(g) o... |
1 | 171767507_3 | 171767507 | o No ý
Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing r... |
1 | 171767507_b0 | 171767507 | Luxfer Holdings PLC, a public limited company incorporated under English law (the "company"), does hereby certify, to such officer's knowledge, that:
The Annual Report on Form 20-F for the year ended December 31, 2016 (the "Form 20-F") of the company fully complies with the requirements of Section 13(a) or 15(d) of th... |
1 | 171767507_b1 | 171767507 | United States Code), each of the undersigned officers of Luxfer Holdings PLC, a public limited company incorporated under English law (the "company"), hereby certifies, to such officer's knowledge, that:
The Annual Report on Form 20-F for the year ended December 31, 2016 (the "Form 20-F") of the company fully complies... |
1 | 171768436_0 | 171768436 | Uniqure N.V.
Form 10-K
Filed on 15-Mar-2017 Period 31-Dec-2016 Accession number: 0001047469-17-001589
Included Items
1. 10-K 2. EX-1.1 3. EX-10.1 4. EX-10.2 5. EX-10.3 6. EX-10.4 7. EX-10.5 8. EX-10.6 9. EX-10.7 10. EX-10.8 11. EX-10.30 12. EX-10.36 13. EX-14.1 14. EX-21.1 15. EX-23.1 16. EX-31.1 17. EX-31.2 18. EX-3... |
1 | 171768436_1 | 171768436 | OR 15(d) OF THESECURITIES EXCHANGEACT OF 1934
For the fiscal year ended December 31, 2016
OR
o
TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THESECURITIES EXCHANGEACT OF 1934
For the transition period from
to
Commission file number: 001-36294
uniQure N.V.
(Exact name of Registrant as specified in its ch... |
1 | 171768436_2 | 171768436 | o No ý
Indicate by check mark if the registrant is not required to file reports pursuant to Section 13 or Section 15(d) of the Act. Yes o No ý
Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the precedin... |
1 | 171768436_3 | 171768436 | definitive proxy or information statements incorporated by reference in Part III of this Form 10-K or any amendment to this Form 10-K.
Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, or a smaller reporting company. See the definitions of "larg... |
1 | 171768436_b0 | 171768436 | . 30, 2014
ft²
ft²
ft²
facility
Leases
Future minimum lease payments
$ 39,355
Lease for facility from AMC located at Meibergdreef in Amsterdam, Netherlands
Leases
Number of facilities leased | facility
2
Area of facility subject to lease (in square feet) | ft²
26,000
Future minimum lease payments
$ 300
... |
1 | 171768436_b1 | 171768436 | in Lexington, Massachusetts, United States | Forecast
Leases
Area of facility subject to lease (in square feet) | ft²
53,000
Leases - Paasheuvelweg, Amsterdam (Details) $ in Thousands
1 Months Ended 12 Months Ended
Mar. 31, 2016
Dec. 31, 2017 Dec. 31, 2016
item
USD ($)
Leases
Future minimum lease payments
... |
1 | 171770263_0 | 171770263 | Corindus Vascular Robotics, Inc.
Form 10-K
Filed on 15-Mar-2017 Period 31-Dec-2016 Accession number: 0001387131-17-001388
Included Items
1. 10-K: ANNUAL REPORT 2. EX-10.42: REGISTRATION RIGHTS
AGREEMENT 3. EX-21: SUBSIDIARIES OF THE REGISTRANT 4. EX-23.1: CONSENT OF ERNST? YOUNG LLP 5. EX-31.1: CERTIFICATION OF CHIEF... |
1 | 171770263_1 | 171770263 | EXCHANGE ACT OF 1934
For the fiscal year ended December 31, 2016
OR
TRANSITION REPORT UNDER SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934
Commission File Number: 001-37406
CORINDUS VASCULAR ROBOTICS, INC.
(Exact name of Registrant as specified in its charter)
Delaware (State or other jurisdiction of i... |
1 | 171770263_2 | 171770263 | Act.
Yes No
Indicate by check mark if the registrant is not required to file reports pursuant to Section 13 or Section 15(d) of the Exchange Act. Yes No
Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 durin... |
1 | 171770263_3 | 171770263 | 's knowledge, in definitive proxy or information statements incorporated by reference in Part III of this Form 10-K or any amendment to this Form 10-K.
Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, or a smaller reporting company. See the def... |
Subsets and Splits
No community queries yet
The top public SQL queries from the community will appear here once available.